An ingestible drug/device combination product designed for targeted delivery of a liquid formulation of tofacitinib into the colon and has potential for improved efficacy driven by increased colonic tissue exposure, while reducing systemic-exposure-associated adverse events.
What did we find?
The Phase 1 clinical trial in healthy adult participants showed that BT-600 was well tolerated and achieved consistent colonic drug delivery with lower systemic exposure than with conventional tofacitinib.8
Key attributes
Category
Drug
Place of origin
Lucknow, UP, India
Reviews
Questions & answers
Ask the supplier — answers are visible to all buyers